Ann Hematol

1. ONCUL Y, Akyay A, Macit B, Ozgen U, et al
   Treatment Outcomes and Factors Affecting Survival in Pediatric Acute Myeloid Leukemia.
   Ann Hematol. 2026;105:141.
   

   >> Share

   
   
2. PAN Y, Shen Y, Miao S, Yao C, et al
   The impact of venetoclax treatment duration on efficacy and hematologic toxicity in acute myeloid leukemia: a systematic review and meta-analysis.
   Ann Hematol. 2026;105:139.
   

   >> Share

   
   
3. ATEF B, El-Ashwah S, Saleh LM, Gawish H, et al
   Potential utility of PPARgamma agonists in targeting chronic myeloid leukemia stem cells.
   Ann Hematol. 2026;105:136.
   

   >> Share

   
   
4. EFENDI ERDEM E, Cecener G, Unal U, Tezcan Unlu H, et al
   Identification of the Philadelphia-like subgroup in Turkish pediatric patients with acute lymphoblastic leukemia.
   Ann Hematol. 2026;105:138.
   

   >> Share

   
   
5. SHELIKHOVA L, Ilyushina M, Khismatullina R, Balashov D, et al
   Long-term outcome of children with acute lymphoblastic leukemia after hematopoietic stem cell transplantation based on ex-vivo alpha-beta T cell depletion.
   Ann Hematol. 2026;105:135.
   

   >> Share

   
   

   
   Blood

6. PARFENOVA EN, Vrdoljak N, Mosca D, Aristizabal-Henao JJ, et al
   Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells.
   Blood. 2026 Feb 26:blood.2025031202. doi: 10.1182/blood.2025031202.
   

   >> Share

   
   
7. HIMONAS E, de Beauchamp L, Zerbst D, Desmares-Romain E, et al
   A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia.
   Blood. 2026 Feb 24:blood.2024027853. doi: 10.1182/blood.2024027853.
   

   >> Share

   
   

   
   Cancer

8. 
   Correction to "Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia".
   Cancer. 2026;132:e70325.
   

   >> Share

   
   

   
   Clin Infect Dis

9. SILLAT MS, Chacko G, Jennifer L
   Intracranial Lesion in a Patient With Chronic Myeloid Leukemia.
   Clin Infect Dis. 2026;82:354-357.
   

   >> Share

   
   

   
   Eur J Haematol

10. GAIDANO G, Danesi R
    Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives.
    Eur J Haematol. 2026 Feb 24. doi: 10.1111/ejh.70144.
    

    >> Share

    
    

    
    Exp Hematol

11. KHAN AB, Huntly BJP
    Taking the direct route: menin inhibitors go straight to the frontline in KMT2A-rearranged acute leukemia.
    Exp Hematol. 2026 Feb 4:105386. doi: 10.1016/j.exphem.2026.105386.
    

    >> Share

    
    

    
    Int J Hematol

12. MIYAZAKI Y, Matsumura I, Arita T, Fukuda R, et al
    Post-marketing surveillance of quizartinib for relapsed or refractory FLT3-ITD-positive acute myeloid leukemia in Japan.
    Int J Hematol. 2026 Feb 26. doi: 10.1007/s12185-026-04181.
    

    >> Share

    
    

    
    J Pediatr Hematol Oncol

13. 
    Isolated Anterior Segment Relapse in a Child With B-cell Precursor Acute Lymphoblastic Leukemia: A Rare Case Report: ERRATUM.
    J Pediatr Hematol Oncol. 2026;48:e117.
    

    >> Share

    
    
14. YANG W, Qin M, Jia C, Zhu G, et al
    Allogeneic Hematopoietic Stem Cell Transplantation for Children With Mixed Phenotype Acute Leukemia: A Single-Center Retrospective Study.
    J Pediatr Hematol Oncol. 2026;48:e69-e77.
    

    >> Share

    
    

    
    Leuk Lymphoma

15. TIAN JX, Liao YX, Wang XX, Wang XD, et al
    Olverembatinib and high-dose methotrexate in acute lymphoblastic leukemia: delayed methotrexate clearance and increased nephrotoxicity.
    Leuk Lymphoma. 2026 Feb 25:1-7. doi: 10.1080/10428194.2026.2634179.
    

    >> Share

    
    
16. REDDY NALLA A, Ganesan K, Muthukumar V, Seshadri N, et al
    Short, safe, and sustainable: outpatient blinatumomab as a bridge and beyond in children with pre B-acute lymphoblastic leukemia.
    Leuk Lymphoma. 2026 Feb 24:1-3. doi: 10.1080/10428194.2026.2634943.
    

    >> Share

    
    
17. MAQBOOL S, Rehman MEU, Khan I, Ibrahim M, et al
    Survival disparities in Philadelphia chromosome-positive vs. Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the era of modern therapeutic approaches: a decade-long surveillance, epidemiology, and end results (SEER) data based
    Leuk Lymphoma. 2026 Feb 23:1-8. doi: 10.1080/10428194.2026.2621822.
    

    >> Share

    
    
18. OHNO H, Maekawa F, Hayashida M, Nakagawa M, et al
    t(14;19)(q32;q13) breakpoints telomeric to BCL3 on 19q13.32 in B-cell lymphomas other than chronic lymphocytic leukemia and long-range structures of der(19)t(14;19) based on optical genome mapping.
    Leuk Lymphoma. 2026 Feb 22:1-11. doi: 10.1080/10428194.2026.2633186.
    

    >> Share

    
    

    
    Leukemia

19. BOHRA A, Hassan R, Zanwar S, Jevremovic D, et al
    Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia.
    Leukemia. 2026 Feb 25. doi: 10.1038/s41375-026-02897.
    

    >> Share

    
    
20. LECORNEC N, Rabian F, Dourthe ME, Chevillon F, et al
    Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.
    Leukemia. 2026 Feb 24. doi: 10.1038/s41375-026-02867.
    

    >> Share

    
    

    
    PLoS One

21. TIRADO HA, Balasundaram N, Jacobs J, Leguay F, et al
    The EAAT1 aspartate/glutamate transporter is dispensable for acute myeloid leukemia cell growth and response to therapy.
    PLoS One. 2026;21:e0329048.
    

    >> Share

    
    
22. TERCAN B
    Robust predictors for drug response of patients with acute myeloid leukemia.
    PLoS One. 2026;21:e0343422.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share